Registration number:
Probus Medicines Limited
for the Year Ended 31 March 2025
Probus Medicines Limited
Contents
|
Company Information |
|
|
Balance Sheet |
|
|
Notes to the Unaudited Financial Statements |
Probus Medicines Limited
Company Information
|
Directors |
Mr J S Casey Dr R Murthy Dr K Smithson |
|
Registered office |
|
Probus Medicines Limited
(Registration number: 13529719)
Balance Sheet as at 31 March 2025
|
Note |
2025 |
2024 |
|
|
Fixed assets |
|||
|
Intangible assets |
|
|
|
|
Tangible assets |
|
|
|
|
|
|
||
|
Current assets |
|||
|
Debtors |
|
|
|
|
Creditors: Amounts falling due within one year |
( |
( |
|
|
Net current liabilities |
( |
( |
|
|
Total assets less current liabilities |
( |
( |
|
|
Provisions for liabilities |
( |
( |
|
|
Net liabilities |
( |
( |
|
|
Capital and reserves |
|||
|
Called up share capital |
|
|
|
|
Retained earnings |
( |
( |
|
|
Shareholders' deficit |
( |
( |
Probus Medicines Limited
(Registration number: 13529719)
Balance Sheet as at 31 March 2025
For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
|
• |
|
|
• |
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. |
Approved and authorised by the
|
......................................... |
Probus Medicines Limited
Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025
|
General information |
The company is a private company limited by share capital, incorporated in England.
The address of its registered office is:
These financial statements were authorised for issue by the
|
Accounting policies |
Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Statement of compliance
These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).
Basis of preparation
These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.
Disclosure of long or short period
Probus Medicines Limited
Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025
Going concern
The financial statements have been prepared on a going concern basis.
The directors acknowledge the company's net current and net liability position at the balance sheet date and the result for the year ended 31 March 2025. This position is expected given that the company was preparing to become operational during the year and only started trading after the year end date on 1 April 2025.
Included within creditors: amounts due within one year is £21,541 (2024: £14,685) which is owed to the parent company and a related entity. The parent company and related entity have provided assurances that this debt will not be called in until the company is in a position to afford the repayment.
On the basis of these assurances, the directors have satisfied themselves that the company is a going concern and have prepared the accounts on this basis.
Tax
Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.
Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.
Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.
Tangible assets
Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.
Depreciation
Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:
|
Asset class |
Depreciation method and rate |
|
Furniture, fittings and equipment |
5 years straight line |
Probus Medicines Limited
Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025
Intangible assets
Separately acquired trademarks and licences are shown at historical cost.
Trademarks, licences (including software) and customer-related intangible assets acquired in a business combination are recognised at fair value at the acquisition date.
Trademarks, licences and customer-related intangible assets have a finite useful life and are carried at cost less accumulated amortisation and any accumulated impairment losses.
Amortisation
Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:
|
Asset class |
Amortisation method and rate |
|
Software |
3 years straight line |
|
Staff numbers |
The average number of persons employed by the company (including directors) during the year, was
Probus Medicines Limited
Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025
|
Intangible assets |
|
Software |
Total |
|
|
Cost or valuation |
||
|
At 1 April 2024 |
|
|
|
At 31 March 2025 |
|
|
|
Amortisation |
||
|
At 1 April 2024 |
|
|
|
Amortisation charge |
|
|
|
At 31 March 2025 |
|
|
|
Carrying amount |
||
|
At 31 March 2025 |
|
|
|
At 31 March 2024 |
|
|
Probus Medicines Limited
Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025
|
Tangible assets |
|
Furniture, fittings and equipment |
Total |
|
|
Cost or valuation |
||
|
At 1 April 2024 |
|
|
|
Additions |
|
|
|
At 31 March 2025 |
|
|
|
Depreciation |
||
|
At 1 April 2024 |
|
|
|
Charge for the year |
|
|
|
At 31 March 2025 |
|
|
|
Carrying amount |
||
|
At 31 March 2025 |
|
|
|
At 31 March 2024 |
|
|
|
Debtors |
|
Current |
2025 |
2024 |
|
Other debtors |
|
|
|
|
|
|
Creditors |
Creditors: amounts falling due within one year
Probus Medicines Limited
Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025
|
Note |
2025 |
2024 |
|
|
Due within one year |
|||
|
Trade creditors |
|
- |
|
|
Amounts owed to group undertakings and undertakings in which the company has a participating interest |
|
|
|
|
Accruals and deferred income |
|
|
|
|
Other creditors |
|
|
|
|
|
|
|
Share capital |
Allotted, called up and not fully paid shares
|
2025 |
2024 |
|||
|
No. |
£ |
No. |
£ |
|
|
|
|
100 |
|
100 |
|
Related party transactions |
The company's immediate parent is Probus Surgery limited, incorporated in England.